Bluejay Diagnostics reports baseline 777-patient sepsis dataset

• The company announced baseline clinical characteristics from its SYMON-II validation study involving 777 evaluable sepsis patients.
• Following the dataset disclosure, the company's shares traded higher at $0.81.
• The company stated it plans to use the forthcoming trial analyses to support a United States regulatory application.

Bluejay Diagnostics (NASDAQ:BJDX) released baseline data for its SYMON-II clinical validation study featuring 777 evaluable sepsis patients.

The preliminary dataset revealed an overall 28-day mortality rate of 18 percent among the enrolled participant cohort.

The baseline results indicated that septic shock affected 39.5 percent of patients and was observed in 56.4 percent of non-survivors.

Following the announcement, Bluejay Diagnostics' share price was up at $0.81 as researchers continue evaluating the measurements.

The validation trial specifically evaluates interleukin-6 biomarker levels in relation to the overall risk of patient mortality.

The diagnostic tool is designed to support clinical evaluations but currently lacks commercial clearance in the United States.

The company stated it expects to leverage the final prognostic performance conclusions to support a future regulatory application.